Full article view 2018-01-30T13:39:05+00:00
Back to News & Insights »

Precision's Messerschmidt and Schafer Discuss Cost of New Gene Therapies With Managed Healthcare Executive

 

In Managed Healthcare Executive, Precision Oncology’s Gerald Messerschmidt and Precision for Value’s Jeremy Schafer are tapped to provide their expert perspectives on the cost and value challenges facing the new class of CAR T-cell therapies.

To read the complete article, click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.